Robert M. Crawford, Jr.

Mr. Crawford’s representative transactions include:

• Royalty Pharma’s purchase of MorphoSys’ rights to receive future royalties on Janssen’s Tremfya in connection with a $2 billion strategic funding partnership as part of MorphoSys’ acquisition of Constellation Pharmaceuticals
• Royalty Pharma’s purchase of certain royalty interests from GlaxoSmithKline 
• The Special Committee of the Board of Directors of NantKwest in connection with NantKwest’s merger with Immunitybio
• Royalty Pharma’s purchase of certain royalty streams from BioHaven Pharmaceuticals
• Royalty Pharma in its purchase of royalties from Minerva Neurosciences for up to $95 million 
• MyoKardia in its $13.1 billion acquisition by Bristol Myers Squibb
• Royalty Pharma’s purchase of certain royalty rights from PTC Therapeutics
• Royalty Pharma’s purchase of certain royalty rights from Ultragenyx Pharmaceutical
• AMAG Pharmaceuticals on the divestment of its women’s health assets 
• AMAG Pharmaceuticals in the sale of its rights to Intrarosa® to Millicent Pharma for up to $125 million
• Chiasma, Inc. in its synthetic royalty financing transaction with HealthCare Royalty Partners
• Royalty Pharma, in its purchase of royalties from a global anti-infectives company
• Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, in its collaboration with Apple, to launch the Heartline™ Study
• Johnson & Johnson in the sale of its BabyCenter business to Everyday Health Group
• Spark Therapeutics, in its $4.8 billion sale to Roche
• Johnson & Johnson in the transfer of collaboration rights and assets to Pharma Mar
• Ipsen, in its $1.31 billion acquisition of Clementia Pharmaceuticals
• Johnson & Johnson, in its strategic healthcare collaboration with Apple to deploy the Apple Watch to detect AFib
• Aegerion Pharmaceuticals, in its exclusive license agreement with Recordati Rare Diseases for the commercialization of Juxtapid^® in Japan, with a total deal value of $110 million plus royalties
• Teva Pharmaceuticals, in the dissolution of its global OTC joint venture with Procter & Gamble Co.
• Keryx in its merger of equals transaction with Akebia valued at $1 billion
• Teva Pharmaceuticals, in its sale of its specialty global women’s health business for a combined value of $2.5 billion, including sale of Paragard®  business to CooperSurgical for $1.1 billion, ex-U.S. women’s health business to CVC Capital Partners for $703 million, and Plan B One-Step® franchise to Foundation Consumer Healthcare for $675 million
• Parexel, in its $5 billion sale to Pamplona
• Teva Pharmaceuticals, in its $40.5 billion acquisition of Allergan’s (fka Actavis/Watson) Global Generic Pharmaceuticals Business.
• Royalty Pharma in its $115 million sale of certain IP and assets to a global pharmaceutical company.
• Teva Pharmaceuticals, in its $410 million exclusive collaboration and license agreement with Heptares Therapeutics Limited regarding its preclinical small-molecule calcitonin gene-related peptide (CGRP) antagonist program.
• Hikma Pharmaceuticals, in its sale of certain generic pharmaceutical products to Renaissance Pharma.
• Teva Pharmaceuticals, in connection with its sale of oncology assets to Ignyta.
• Cephalon, in its exclusive license agreement with Eagle Pharmaceuticals related to BendekaTM with a total deal value in excess of $120 million, plus royalties.
• Cipla, in connection with its $550 million acquisition of InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc.
• Teva Pharmaceuticals, in its $3.5 billion acquisition of Auspex.
• Lupin, in connection with exclusive collaboration and license agreement regarding development and commercialization of innovative drug products and new platform technologies.
• Syqe Medical, in connection with $20 million investment by Philip Morris and related exclusive license and development agreement regarding innovative inhaler products.
• Pharmascience, in connection with its strategic partnership with Bion Pharmaceuticals.
• Teva Pharmaceuticals, in connection with patent license and settlement agreements related to settlements of various brand and generic pharmaceutical patent litigation matters.
• Fresenius Kabi, in connection with patent license and settlement agreements related to settlements of various pharmaceutical patent litigation matters.
• Lupin, in connection with patent license and settlement agreements related to settlements of various pharmaceutical patent litigation matters.
• West-Ward Pharmaceuticals, in connection with patent license and settlement agreements related to settlements of various pharmaceutical patent litigation matters.
• Glenmark, in connection with patent license and settlement agreements related to settlements of various pharmaceutical patent litigation matters.
• Alere, Inc., with respect to a 50/50 joint venture with The Procter & Gamble Company for existing and to-be-developed consumer diagnostic products.
• Alere, Inc., with respect to its acquisition of ACON Laboratories Inc.'s worldwide lateral flow immunoassay business and its manufacturing facility in Hangzhou, China.
• Alere, Inc., with respect to its acquisition of Biosite, Inc., a leading provider of rapid diagnostic products.
• Citrix Systems, Inc., in its $1.8 billion spin-out of its GoTo family of products.
• Citrix Systems, Inc., with respect to its strategic alliance with Cisco for desktop virtualization products.
• Citrix Systems, Inc., with respect to a collaboration agreement with Microsoft regarding virtual desktops.
• Citrix Systems, Inc., with respect to a collaboration agreement with Intel regarding a bare-metal hypervisor.
• Thoma Bravo, LLC, in its acquisition of Roadnet Technologies Inc. (transportation and logistics solutions division formerly known as UPS Logistics Technologies) from United Parcel Service, Inc.